

United States Patent [19]

Froesch et al.

[11] Patent Number: 4,988,675

[45] Date of Patent: Jan. 29, 1991

[54] METHOD FOR PREVENTING SECONDARY EFFECTS

[75] Inventors: Ernst R. Froesch, Erlenbach;
Hans-Peter Guler, Adliswil;
Christoph Schmid, Zurich; Jürgen
Zapf, Zurich, all of Switzerland

[73] Assignee: Ciba-Geigy Corporation, Ardsley,
N.Y.

[21] Appl. No.: 301,680

[22] Filed: Jan. 25, 1989

[30] Foreign Application Priority Data

Feb. 5, 1988 [CH] Switzerland 810072/88

[51] Int. Cl.⁵ A61K 37/26; A61K 37/36

[52] U.S. Cl. 514/4; 514/12

[58] Field of Search 514/4, 12

[56] References Cited

FOREIGN PATENT DOCUMENTS

123228 10/1984 European Pat. Off. .

OTHER PUBLICATIONS

Scheiwiller et al., Nature, vol. 323, 11, Sep. 1986, pp. 169-171.

Stedman, Stedman's Medical Dictionary, p. 880, 24th Edition, 1982, Williams & Wilkins.

Guler et al., New England Journal of Medicine, vol. 317, No. 3, pp. 137-140, (1987).

Primary Examiner—Howard E. Schain

Assistant Examiner—Choon Koh

Attorney, Agent, or Firm—Henry P. Nowak; Irving M. Fishman; JoAnn Villamizar

[57] ABSTRACT

The invention concerns a method for treating and preventing secondary effects of hyperinsulinemia by application of insulin-like growth factor I (IGF I), and pharmaceutical compositions comprising IGF I which are useful for this purpose.

10 Claims, 3 Drawing Sheets